Preserving anti-platelet activity of aspirin by preventing hydrolysis

The hydrolysis of aspirin markedly reduces its anti-platelet activity. This has prevented the development of an effective IV formulation of aspirin that would improve the treatment of acute coronary syndromes. We have developed a formulation that we believe would resist hydrolysis and preserve platelet inhibition.